Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656670 | 0.91 | CNR1 (0.40) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| SCHEMBL19640646 | 0.90 | CNR1 (0.40) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| SCHEMBL19640645 | 0.90 | CNR1 (0.40) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| SCHEMBL21644807 | 0.88 | CNR1 (0.44) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| SCHEMBL19328506 | 0.88 | CNR1 (0.44) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| SCHEMBL19640637 | 0.85 | CNR1 (0.38) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| SCHEMBL19640643 | 0.85 | CNR1 (0.38) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| SCHEMBL17790864 | 0.85 | CNR1 (0.41) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| Methane SCHEMBL19640640 | 0.83 | CNR1 (0.39) | CNR1ALDH1A1CNR2ALOX12FAAH | |
| SCHEMBL19343062 | 0.82 | CNR1 (0.47) | CNR1ALDH1A1CNR2ALOX12FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | CNR1 1037/4885ALDH1A1 1220/4885CNR2 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.